Market Cap (In HKD)
15.61 Billion
Revenue (In HKD)
125.93 Million
Net Income (In HKD)
-844.46 Million
Avg. Volume
1.72 Million
- Currency
- HKD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 14.34-52.15
- PE
- -
- EPS
- -
- Beta Value
- 1.942
- ISIN
- KYG3224E1061
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Yongqing Luo
- Employee Count
- -
- Website
- https://www.everestmedicines.com
- Ipo Date
- 2020-10-09
- Details
- Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
More Stocks
-
CASTCastro Model Ltd.
CAST
-
BRIL
-
LKMNFLucky Minerals Inc.
LKMNF
-
RTKM
-
FINMFinancière Marjos SA
FINM
-
DEDIDedicare AB (publ)
DEDI
-
CMTNFCullinan Metals Corp.
CMTNF
-
IDHC